Study of Urinary Calprotectin Levels in Type 2 Diabetics with Peripheral Arterial Disease

Abstract

Objective The aim of the present study is to investigate the association of urinary calprotectin levels with lower extremities peripheral arterial disease (LEPAD) in patients with type 2 diabetes mellitus (T2DM). Background calprotectin is formed by two different calcium- binding proteins; it constitutes about 40% of neutrophils all cytosolic proteins. Calprotectin or its components (S100A8/S100A9) consider as a potential therapeutic target in inflammatory conditions including diabetes mellitus. The ankle-brachial index of less than 0.9 was applied for LEPAD diagnosis. Method we recruited 60 patients with T2DM; half of them had LEPAD and a healthy control group consists of 30 participants. Urinary Calprotectin and high sensitivity CRP (hsCRP) were measured by enzyme-linked immunoassay kit. Results Urinary calprotectin level was statistically significant higher among the three participating groups (p value <0.001), however, in post-hoc analysis there was no difference between patients with type 2 diabetes mellitus with or without LEPAD (p value =0.993). However, urinary calprotectin was weakly associated with LEPAD severity (p value = 0.175, p value = 0.06 respectively).There was a statistically significant positive correlation between urinary calprotectin level and hsCRP (r = 0.65, p value 0.001). Conclusion Urinary calprotectin cannot be used as a biomarker for LEPAD in T2DM.